Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 19 | 2007 | 257 | 1.200 |
Why?
|
| Islets of Langerhans Transplantation | 17 | 2006 | 170 | 0.920 |
Why?
|
| Pancreas Transplantation | 7 | 2007 | 21 | 0.850 |
Why?
|
| Graft Survival | 12 | 2007 | 278 | 0.830 |
Why?
|
| Leukocyte Common Antigens | 10 | 2006 | 54 | 0.820 |
Why?
|
| Plasma Gases | 4 | 2022 | 5 | 0.800 |
Why?
|
| Graft Rejection | 9 | 2004 | 256 | 0.540 |
Why?
|
| Diabetes Mellitus, Experimental | 5 | 2018 | 193 | 0.420 |
Why?
|
| Bandages | 1 | 2012 | 14 | 0.410 |
Why?
|
| Antibodies, Monoclonal | 7 | 2006 | 864 | 0.400 |
Why?
|
| Warfare | 1 | 2012 | 33 | 0.400 |
Why?
|
| Hemostatics | 1 | 2012 | 26 | 0.400 |
Why?
|
| Tissue Donors | 8 | 2007 | 131 | 0.380 |
Why?
|
| Military Personnel | 1 | 2012 | 97 | 0.370 |
Why?
|
| Hemorrhage | 1 | 2012 | 276 | 0.350 |
Why?
|
| Islets of Langerhans | 8 | 2006 | 267 | 0.340 |
Why?
|
| Tissue and Organ Procurement | 4 | 2007 | 35 | 0.330 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 234 | 0.330 |
Why?
|
| Ursidae | 2 | 2020 | 12 | 0.320 |
Why?
|
| Transplantation Tolerance | 3 | 2006 | 65 | 0.300 |
Why?
|
| CD40 Ligand | 4 | 2005 | 162 | 0.290 |
Why?
|
| Transplantation Immunology | 3 | 2005 | 23 | 0.270 |
Why?
|
| Transplantation, Homologous | 10 | 2006 | 230 | 0.250 |
Why?
|
| Immunosuppressive Agents | 6 | 2001 | 291 | 0.230 |
Why?
|
| Bacterial Infections | 2 | 2004 | 139 | 0.230 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 275 | 0.230 |
Why?
|
| Osteomyelitis | 1 | 2003 | 22 | 0.220 |
Why?
|
| Aspergillosis | 1 | 2003 | 33 | 0.220 |
Why?
|
| Spinal Diseases | 1 | 2003 | 47 | 0.220 |
Why?
|
| Hibernation | 2 | 2020 | 10 | 0.220 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 1113 | 0.210 |
Why?
|
| Sarcoma | 1 | 2022 | 34 | 0.200 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 31 | 0.200 |
Why?
|
| Mice, Inbred BALB C | 9 | 2006 | 880 | 0.200 |
Why?
|
| RNA, Neoplasm | 1 | 2021 | 34 | 0.190 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 59 | 0.190 |
Why?
|
| Cholangiocarcinoma | 1 | 2021 | 25 | 0.190 |
Why?
|
| Antibodies, Blocking | 1 | 2001 | 41 | 0.180 |
Why?
|
| Antigens, Differentiation | 4 | 2006 | 139 | 0.180 |
Why?
|
| Hemostasis | 1 | 2020 | 27 | 0.180 |
Why?
|
| Amnion | 1 | 2018 | 9 | 0.160 |
Why?
|
| Chorion | 1 | 2018 | 6 | 0.160 |
Why?
|
| Achilles Tendon | 1 | 2018 | 6 | 0.160 |
Why?
|
| Diabetic Nephropathies | 2 | 2004 | 38 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 138 | 0.160 |
Why?
|
| Tendon Injuries | 1 | 2018 | 16 | 0.160 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2018 | 35 | 0.150 |
Why?
|
| Histones | 1 | 2021 | 460 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 396 | 0.150 |
Why?
|
| Insulin | 6 | 2005 | 682 | 0.140 |
Why?
|
| Antibodies | 1 | 1998 | 176 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 10 | 2006 | 3156 | 0.140 |
Why?
|
| Body Constitution | 1 | 1997 | 15 | 0.140 |
Why?
|
| Histocompatibility Testing | 1 | 1997 | 31 | 0.140 |
Why?
|
| Blood Coagulation | 1 | 2017 | 50 | 0.140 |
Why?
|
| Animals | 23 | 2020 | 19481 | 0.140 |
Why?
|
| Immune Tolerance | 3 | 2005 | 169 | 0.140 |
Why?
|
| RNA, Messenger | 2 | 2021 | 1460 | 0.140 |
Why?
|
| Humans | 30 | 2022 | 58814 | 0.130 |
Why?
|
| Osteoporosis | 3 | 2002 | 137 | 0.130 |
Why?
|
| Immunotherapy | 1 | 1998 | 224 | 0.130 |
Why?
|
| Kidney | 2 | 1997 | 391 | 0.130 |
Why?
|
| Immunoglobulins | 1 | 1994 | 76 | 0.120 |
Why?
|
| Immunization, Passive | 1 | 1994 | 100 | 0.120 |
Why?
|
| Incidence | 5 | 2004 | 1226 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2020 | 617 | 0.120 |
Why?
|
| Mice | 14 | 2006 | 10184 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 1 | 1994 | 69 | 0.110 |
Why?
|
| RNA, Small Interfering | 3 | 2022 | 849 | 0.110 |
Why?
|
| Male | 19 | 2020 | 27252 | 0.110 |
Why?
|
| Cytomegalovirus | 1 | 1994 | 88 | 0.110 |
Why?
|
| Ischemia | 1 | 1995 | 188 | 0.110 |
Why?
|
| Heart Arrest | 1 | 1995 | 153 | 0.110 |
Why?
|
| Time Factors | 7 | 2006 | 3544 | 0.110 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 1360 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2003 | 2875 | 0.100 |
Why?
|
| Postoperative Complications | 3 | 2002 | 1114 | 0.100 |
Why?
|
| Adjuvants, Immunologic | 2 | 2003 | 228 | 0.090 |
Why?
|
| Gene Silencing | 2 | 2020 | 376 | 0.090 |
Why?
|
| Cyclosporins | 3 | 1987 | 7 | 0.090 |
Why?
|
| Cell Death | 2 | 2022 | 265 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 301 | 0.090 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2007 | 21 | 0.090 |
Why?
|
| Female | 13 | 2022 | 30539 | 0.080 |
Why?
|
| Antigens | 2 | 2006 | 146 | 0.080 |
Why?
|
| Apoptosis | 2 | 2022 | 1034 | 0.080 |
Why?
|
| Seasons | 2 | 2020 | 129 | 0.080 |
Why?
|
| Antilymphocyte Serum | 3 | 1998 | 21 | 0.080 |
Why?
|
| Graft Enhancement, Immunologic | 2 | 2003 | 10 | 0.080 |
Why?
|
| Health Care Rationing | 1 | 2007 | 20 | 0.070 |
Why?
|
| Middle Aged | 10 | 2007 | 16114 | 0.070 |
Why?
|
| Acyclovir | 2 | 1997 | 20 | 0.070 |
Why?
|
| Organ Transplantation | 1 | 2007 | 51 | 0.070 |
Why?
|
| Death | 1 | 2006 | 24 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 158 | 0.070 |
Why?
|
| Reoperation | 1 | 2007 | 246 | 0.060 |
Why?
|
| Up-Regulation | 3 | 2020 | 362 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 1997 | 5920 | 0.060 |
Why?
|
| Skin Transplantation | 3 | 2005 | 151 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2006 | 111 | 0.060 |
Why?
|
| Rats | 4 | 2018 | 1901 | 0.060 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2002 | 21 | 0.060 |
Why?
|
| Antigens, CD | 5 | 2006 | 341 | 0.060 |
Why?
|
| Immunoconjugates | 2 | 2003 | 84 | 0.060 |
Why?
|
| CTLA-4 Antigen | 4 | 2006 | 65 | 0.060 |
Why?
|
| Diabetes Mellitus | 2 | 2006 | 531 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2005 | 646 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2004 | 188 | 0.050 |
Why?
|
| Cell Separation | 1 | 2002 | 147 | 0.050 |
Why?
|
| Alendronate | 1 | 2002 | 14 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2022 | 50 | 0.050 |
Why?
|
| Chronic Disease | 2 | 1997 | 727 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2022 | 109 | 0.050 |
Why?
|
| Living Donors | 2 | 2004 | 62 | 0.050 |
Why?
|
| Leucovorin | 1 | 2021 | 9 | 0.050 |
Why?
|
| Bone Remodeling | 1 | 2001 | 25 | 0.050 |
Why?
|
| Adult | 8 | 2006 | 15594 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2022 | 124 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2021 | 54 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2002 | 2316 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2021 | 132 | 0.050 |
Why?
|
| Cell Division | 1 | 2022 | 440 | 0.050 |
Why?
|
| Models, Immunological | 1 | 2001 | 79 | 0.050 |
Why?
|
| Antithrombin III | 1 | 2020 | 14 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 301 | 0.050 |
Why?
|
| Bone Resorption | 1 | 2000 | 49 | 0.050 |
Why?
|
| Muromonab-CD3 | 2 | 1997 | 7 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2001 | 192 | 0.040 |
Why?
|
| Infection Control | 1 | 2001 | 92 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2001 | 254 | 0.040 |
Why?
|
| Blood Glucose | 2 | 1997 | 467 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 432 | 0.040 |
Why?
|
| Cadaver | 2 | 2004 | 99 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 806 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2020 | 187 | 0.040 |
Why?
|
| Rupture | 1 | 2018 | 22 | 0.040 |
Why?
|
| Cell Movement | 1 | 2001 | 419 | 0.040 |
Why?
|
| Monocytes | 1 | 2001 | 350 | 0.040 |
Why?
|
| Creatinine | 2 | 2002 | 121 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2001 | 549 | 0.040 |
Why?
|
| Ganciclovir | 1 | 1997 | 19 | 0.040 |
Why?
|
| Hospitalization | 2 | 1996 | 1268 | 0.040 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1997 | 35 | 0.040 |
Why?
|
| Osteocalcin | 3 | 2002 | 48 | 0.040 |
Why?
|
| Transplantation, Isogeneic | 1 | 1997 | 8 | 0.040 |
Why?
|
| Body Surface Area | 1 | 1997 | 13 | 0.040 |
Why?
|
| Tacrolimus | 1 | 1997 | 39 | 0.040 |
Why?
|
| Cyclosporine | 1 | 1997 | 56 | 0.030 |
Why?
|
| Cytokines | 1 | 2001 | 903 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 1996 | 53 | 0.030 |
Why?
|
| Exons | 1 | 1997 | 192 | 0.030 |
Why?
|
| Bone Density | 3 | 2002 | 173 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 1997 | 181 | 0.030 |
Why?
|
| Thymectomy | 2 | 2006 | 33 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1997 | 485 | 0.030 |
Why?
|
| Waiting Lists | 2 | 2007 | 48 | 0.030 |
Why?
|
| Acute Disease | 2 | 1998 | 649 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 1995 | 107 | 0.030 |
Why?
|
| Body Weight | 1 | 1997 | 376 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 1997 | 313 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1994 | 27 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1994 | 32 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 1997 | 925 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2005 | 146 | 0.030 |
Why?
|
| Temperature | 1 | 1995 | 299 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 569 | 0.030 |
Why?
|
| Kinetics | 1 | 1995 | 728 | 0.030 |
Why?
|
| Virus Diseases | 1 | 1994 | 110 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 1993 | 16 | 0.030 |
Why?
|
| Morbidity | 1 | 1993 | 105 | 0.030 |
Why?
|
| Abatacept | 2 | 2003 | 63 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2007 | 5096 | 0.030 |
Why?
|
| Communicable Diseases | 1 | 1993 | 81 | 0.030 |
Why?
|
| Risk Factors | 2 | 2004 | 4970 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 2039 | 0.020 |
Why?
|
| Survival Analysis | 1 | 1993 | 550 | 0.020 |
Why?
|
| Age Factors | 2 | 2007 | 1514 | 0.020 |
Why?
|
| Preoperative Care | 2 | 1996 | 171 | 0.020 |
Why?
|
| Liver Transplantation | 2 | 2007 | 185 | 0.020 |
Why?
|
| Mice, Inbred NOD | 2 | 2003 | 509 | 0.020 |
Why?
|
| Amino Acids | 2 | 2001 | 140 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2005 | 1975 | 0.020 |
Why?
|
| Lymphocyte Activation | 2 | 2003 | 736 | 0.020 |
Why?
|
| Length of Stay | 1 | 1993 | 759 | 0.020 |
Why?
|
| Pancreatectomy | 2 | 1986 | 85 | 0.020 |
Why?
|
| Calcium | 2 | 2002 | 550 | 0.020 |
Why?
|
| Dogs | 2 | 1986 | 305 | 0.020 |
Why?
|
| Cold Ischemia | 1 | 2007 | 2 | 0.020 |
Why?
|
| Lung Transplantation | 1 | 2007 | 47 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1986 | 55 | 0.020 |
Why?
|
| Biomarkers | 2 | 2002 | 1199 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 187 | 0.020 |
Why?
|
| Fasting | 1 | 1986 | 50 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2006 | 38 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 1986 | 95 | 0.020 |
Why?
|
| Methods | 1 | 2005 | 39 | 0.020 |
Why?
|
| Lymphocyte Transfusion | 1 | 2005 | 37 | 0.020 |
Why?
|
| Postoperative Care | 1 | 1986 | 112 | 0.020 |
Why?
|
| Isoantibodies | 1 | 2005 | 32 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2007 | 157 | 0.020 |
Why?
|
| Adolescent | 3 | 2004 | 5862 | 0.020 |
Why?
|
| Raffinose | 1 | 2005 | 2 | 0.020 |
Why?
|
| Organ Preservation Solutions | 1 | 2005 | 4 | 0.020 |
Why?
|
| Allopurinol | 1 | 2005 | 17 | 0.020 |
Why?
|
| Administration, Oral | 1 | 1986 | 343 | 0.020 |
Why?
|
| Glutathione | 1 | 2005 | 50 | 0.020 |
Why?
|
| Models, Animal | 1 | 2005 | 219 | 0.010 |
Why?
|
| Adenosine | 1 | 2005 | 68 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 45 | 0.010 |
Why?
|
| New England | 1 | 2004 | 267 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2006 | 333 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 370 | 0.010 |
Why?
|
| Interleukin-7 | 1 | 2003 | 30 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 397 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2003 | 63 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2004 | 249 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2007 | 890 | 0.010 |
Why?
|
| Ficoll | 1 | 2002 | 4 | 0.010 |
Why?
|
| Filtration | 1 | 2002 | 22 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2003 | 162 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 1218 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2003 | 142 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 1308 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2002 | 42 | 0.010 |
Why?
|
| Everolimus | 1 | 2001 | 17 | 0.010 |
Why?
|
| Calcineurin Inhibitors | 1 | 2001 | 22 | 0.010 |
Why?
|
| Algorithms | 1 | 2007 | 981 | 0.010 |
Why?
|
| Infection Control Practitioners | 1 | 2001 | 2 | 0.010 |
Why?
|
| Facility Regulation and Control | 1 | 2001 | 3 | 0.010 |
Why?
|
| Professional Staff Committees | 1 | 2001 | 5 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2005 | 605 | 0.010 |
Why?
|
| Sirolimus | 1 | 2001 | 72 | 0.010 |
Why?
|
| Physician Executives | 1 | 2001 | 28 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2011 | 0.010 |
Why?
|
| Aged | 3 | 2004 | 13207 | 0.010 |
Why?
|
| Italy | 1 | 2001 | 62 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 2001 | 43 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2001 | 44 | 0.010 |
Why?
|
| Nursing Staff | 1 | 2001 | 41 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2003 | 536 | 0.010 |
Why?
|
| Prednisone | 1 | 2000 | 79 | 0.010 |
Why?
|
| Calcineurin | 1 | 2001 | 42 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2005 | 698 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 1535 | 0.010 |
Why?
|
| Hypertension | 1 | 2004 | 598 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2004 | 1811 | 0.010 |
Why?
|
| Antigens, CD19 | 1 | 1997 | 18 | 0.010 |
Why?
|
| Rabbits | 1 | 1998 | 330 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2001 | 1198 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1997 | 191 | 0.010 |
Why?
|
| Rats, Inbred Lew | 2 | 1987 | 109 | 0.010 |
Why?
|
| Prognosis | 1 | 2001 | 1561 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1996 | 49 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1998 | 679 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1996 | 170 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2001 | 956 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 711 | 0.010 |
Why?
|
| Child | 1 | 2004 | 4237 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2001 | 3070 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2000 | 2442 | 0.010 |
Why?
|
| United States | 1 | 2007 | 7432 | 0.010 |
Why?
|
| Rats, Inbred ACI | 1 | 1987 | 6 | 0.000 |
Why?
|
| Rats, Inbred BN | 1 | 1987 | 25 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1987 | 252 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1987 | 347 | 0.000 |
Why?
|
| Transplantation, Autologous | 1 | 1985 | 115 | 0.000 |
Why?
|
| Swine | 1 | 1985 | 337 | 0.000 |
Why?
|
| Spleen | 1 | 1985 | 485 | 0.000 |
Why?
|
| Glucose | 1 | 1985 | 440 | 0.000 |
Why?
|